Matches in Wikidata for { <http://www.wikidata.org/entity/Q64150817> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q64150817 description "clinical trial" @default.
- Q64150817 description "ensayu clínicu" @default.
- Q64150817 description "klinisch onderzoek" @default.
- Q64150817 description "клінічне випробування" @default.
- Q64150817 description "կլինիկական փորձարկում" @default.
- Q64150817 name "Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)" @default.
- Q64150817 type Item @default.
- Q64150817 label "Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)" @default.
- Q64150817 prefLabel "Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)" @default.
- Q64150817 P1132 Q64150817-DC9013DD-38FD-46AE-B2A8-0ED25967E178 @default.
- Q64150817 P1476 Q64150817-2A1FA66F-0927-406F-B908-EF14E3EB5C27 @default.
- Q64150817 P17 Q64150817-2DEFC13C-9DB3-4C61-8E1F-B5451AEFC146 @default.
- Q64150817 P17 Q64150817-4BCF0FDB-C158-442A-A9BE-6CF0FD0D23B7 @default.
- Q64150817 P17 Q64150817-55E731DD-5D41-4FE4-9D3D-DFCCC0C9AC50 @default.
- Q64150817 P17 Q64150817-C0649C32-6AB9-494D-99E4-3C1EEF37F5F0 @default.
- Q64150817 P2899 Q64150817-6BB862E3-D8B4-4E16-984D-67067A1F663A @default.
- Q64150817 P3098 Q64150817-94C3ADA9-6A44-4B12-8D88-3942648ADEF1 @default.
- Q64150817 P31 Q64150817-29E99391-FAA4-4214-90FC-7A40D53CC248 @default.
- Q64150817 P4844 Q64150817-02B9C429-F07C-49BF-A5E8-37317B13BCBE @default.
- Q64150817 P580 Q64150817-BC2C67D7-E004-4D75-B6D3-6361147F9723 @default.
- Q64150817 P582 Q64150817-9B1BC996-84B0-4CD2-9251-F08BDF0D1FF6 @default.
- Q64150817 P6099 Q64150817-21FDB51C-9E85-4284-B0AF-4E129D25FF6A @default.
- Q64150817 P8363 Q64150817-B8C94FFA-7EC3-49E4-8483-0AF412743DAC @default.
- Q64150817 P1132 "+308" @default.
- Q64150817 P1476 "A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors" @default.
- Q64150817 P17 Q17 @default.
- Q64150817 P17 Q30 @default.
- Q64150817 P17 Q408 @default.
- Q64150817 P17 Q801 @default.
- Q64150817 P2899 "+18" @default.
- Q64150817 P3098 "NCT03179436" @default.
- Q64150817 P31 Q30612 @default.
- Q64150817 P4844 Q13896859 @default.
- Q64150817 P580 "2017-07-02T00:00:00Z" @default.
- Q64150817 P582 "2023-03-08T00:00:00Z" @default.
- Q64150817 P6099 Q5452194 @default.
- Q64150817 P8363 Q78089383 @default.